Novartis presents Phase 3 remibrutinib results at Toronto MS conference
Novartis presented Phase 3 results for remibrutinib at an MS conference in Toronto on Friday. In the REMODEL-1 and REMODEL-2 studies, the drug reduced annualized relapse rates by 35.2% and 31.2% versus Sanofi’s Aubagio in relapsing multiple sclerosis. The…
